Quick Answer
Eton Pharmaceuticals, Inc. reported Research And Development Expense of $7.77 million for the year ending 2025.
- Eton Pharmaceuticals, Inc. showed an increase of +138.6% in Research And Development Expense from 2024 to 2025.
- This data is from Eton Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2017: $1.56 million | Q1 2018: $1.27 million | Q2 2018: $1.71 million | Q3 2018: $1.54 million | Q1 2019: $6.47 million | Q2 2019: $1.44 million | Q3 2019: $3.42 million | Q1 2020: $6.27 million | Q2 2020: $1.61 million | Q3 2020: $2.83 million | Q1 2021: $886.0 thousand | Q2 2021: $1.99 million | Q3 2021: $2.68 million | Q1 2022: $1.62 million | Q2 2022: $690.0 thousand | Q3 2022: $744.0 thousand | Q1 2023: $535.0 thousand | Q2 2023: $1.13 million | Q3 2023: $615.0 thousand | Q1 2024: $651.0 thousand | Q2 2024: $2.97 million | Q3 2024: $505.0 thousand | Q1 2025: $1.16 million | Q2 2025: $3.71 million | Q3 2025: $1.11 million.
- Over the full 8 years of available data (2018 to 2025), Eton Pharmaceuticals, Inc.'s Research And Development Expense has grown by 38.0%.
- Historical annual values: Fiscal year 2025: $7.77 million | Fiscal year 2024: $3.26 million | Fiscal year 2023: $3.32 million | Fiscal year 2022: $4.00 million | Fiscal year 2021: $6.24 million | Fiscal year 2020: $14.10 million | Fiscal year 2019: $11.56 million | Fiscal year 2018: $5.63 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: